ID Name Structure References (top 5) Molecular Target(s)
1ID:621
BERGAPTEN


NSC#:95437
Aldrich#:275727
Aldrich#:65320

Freqency:
in 8 ingredients:

  • 85
  • 93
  • 177
  • 412
  • 454
  • 584
  • 711
  • 733
  • in 61 recipes:

  • 4
  • 22
  • 37
  • 51
  • 55
  • 61
  • 63
  • 69
  • 71
  • 73
  • 77
  • 83
  • 102
  • 106
  • 109
  • 111
  • 121
  • 158
  • 161
  • 172
  • 174
  • 181
  • 193
  • 203
  • 208
  • 223
  • 229
  • 231
  • 268
  • 292
  • 299
  • 301
  • 303
  • 309
  • 313
  • 315
  • 319
  • 321
  • 327
  • 331
  • 333
  • 339
  • 342
  • 345
  • 352
  • 359
  • 382
  • 385
  • 388
  • 398
  • 405
  • 411
  • 438
  • 452
  • 456
  • 467
  • 470
  • 472
  • 474
  • 504
  • 507

  • Properties
    C12H8O4    216.19





    1:  Oudesluys-Murphy AM, Oudesluys N.
    Tea: not immoral, illegal, or fattening, but is it innocuous?
    Lancet.    impact factor:   10.197
    2002;  360(9336): 878

    2:  Prapaipong H, Berenbaum MR, Schuler MA.
    Transcriptional regulation of the Papilio polyxenes CYP6B1 gene.
    Nucleic Acids Res.    impact factor:   5.748
    1994;  22(15): 3210-7

    3:  Zucchi A, Raho E, Marconi B, Nicoli S, Santini M, Allegra F, Colombo P, Bettini R, Santi P.
    Plasma and skin concentration of 5-methoxypsoralen in psoriatic patients after oral administration.
    J Invest Dermatol.    impact factor:   4.903
    2001;  117(2): 379-82

    4:  Mengeaud V, Ortonne JP.
    PUVA (5-methoxypsoralen plus UVA) enhances melanogenesis and modulates expression of melanogenic proteins in cultured melanocytes.
    J Invest Dermatol.    impact factor:   4.903
    1996;  107(1): 57-62

    5:  Malhotra S, Bailey DG, Paine MF, Watkins PB.
    Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins.
    Clin Pharmacol Ther.    impact factor:   4.846
    2001;  69(1): 14-23

    ARG
    C-AMP
    LC
    MET
    NAIP
    P450
    PEST
    ROS
    SAP
    STEP
    PKC
     
    Time used: 610 milliseconds.

    Webpage designed by Dr. Xueliang Fang, last updated on 3/10/2005